Literature DB >> 9865497

Effects of IFN alpha on late stages of HIV-1 replication cycle.

F Dianzani1, C Castilletti, M Gentile, H R Gelderblom, F Frezza, M R Capobianchi.   

Abstract

IFN alpha causes a modest reduction of HIV-1 expression in chronically infected monocytoid U937 cells. However, the ratio between cell-associated and shed viral p24 antigen is altered, being the cell-associated fraction dose-dependently enhanced by IFN. Furthermore, a significant decrease of infectivity of both cell-associated and shed material is observed. Transmission electron microscopy of IFN-treated cells revealed virus assembly being strongly inhibited, with the production of morphologically altered (tear-drop shaped) virus particles. Proteolytic processing of gag proteins appeared to be normal in IFN-treated cultures. However, virions shed from IFN-treated cells showed a markedly reduced incorporation of virus-specific gp120 and cell-derived ICAM-1 by the virus envelope. Additionally, these particles showed a significantly decreased ability to become bound to CD4+ target cells, accounting for, at least in part, the observed decrease of infectivity. Taken together, the data suggest that, in chronically infected cells, IFN alpha can affect late stages of HIV-1 replication, by inhibiting virus assembly and release, and by reducing the infectivity of shed virions. The latter effect seems to be due, at least in part, to altered incorporation of surface glycoproteins and defective particle formation. The relationship between impaired gp120 incorporation and altered morphogenesis of HIV-1 virions is under investigation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9865497     DOI: 10.1016/s0300-9084(99)80028-5

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  15 in total

1.  Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

Authors:  David M Asmuth; Robert L Murphy; Susan L Rosenkranz; Juan J L Lertora; Shyam Kottilil; Yoninah Cramer; Ellen S Chan; Robert T Schooley; Charles R Rinaldo; Nathan Thielman; Xiao-Dong Li; Sharon M Wahl; Jessica Shore; Jennifer Janik; Richard A Lempicki; Yaa Simpson; Richard B Pollard
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

2.  Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.

Authors:  Caitlin M Miller; Hisashi Akiyama; Luis M Agosto; Ann Emery; Chelsea R Ettinger; Ronald I Swanstrom; Andrew J Henderson; Suryaram Gummuluru
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

3.  The IFITM proteins inhibit HIV-1 infection.

Authors:  Jennifer Lu; Qinghua Pan; Liwei Rong; Wei He; Shan-Lu Liu; Chen Liang
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

Review 4.  Insights into cellular factors that regulate HIV-1 replication in human cells.

Authors:  Andrew M L Lever; Kuan-Teh Jeang
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

Review 5.  Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.

Authors:  Andrey Tokarev; Mark Skasko; Kathleen Fitzpatrick; John Guatelli
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

6.  Partial inhibition of human immunodeficiency virus replication by type I interferons: impact of cell-to-cell viral transfer.

Authors:  Daniela Vendrame; Marion Sourisseau; Virginie Perrin; Olivier Schwartz; Fabrizio Mammano
Journal:  J Virol       Date:  2009-08-12       Impact factor: 5.103

7.  Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques.

Authors:  D M Asmuth; K Abel; M D George; S Dandekar; R B Pollard; C J Miller
Journal:  J Med Primatol       Date:  2008-02       Impact factor: 0.667

8.  Effect of type-I interferon on retroviruses.

Authors:  Esperanza Gómez-Lucía; Victorio M Collado; Guadalupe Miró; Ana Doménech
Journal:  Viruses       Date:  2009-10-27       Impact factor: 5.048

9.  90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1.

Authors:  Veronika Lodermeyer; Kristina Suhr; Nicola Schrott; Christian Kolbe; Christina M Stürzel; Daniela Krnavek; Jan Münch; Christian Dietz; Tanja Waldmann; Frank Kirchhoff; Christine Goffinet
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

10.  The interferon response inhibits HIV particle production by induction of TRIM22.

Authors:  Stephen D Barr; James R Smiley; Frederic D Bushman
Journal:  PLoS Pathog       Date:  2008-02-29       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.